Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

NCT03364231 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT03364231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2017
Completion date
February 15, 2022
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma, non follicular indolent non-hodgkin lymphoma, waldenstrom macroglobulinemia